This page offers you with an array of useful resources related to COVID-19 and the liver, including articles, accounts from healthcare professionals, calls for abstracts, and statements.
You are welcome to send suggestions of materials to include to us at email@example.com
EASL has launched a series of webinars relating to COVID-19. The participants are world-renowned scientists and clinicians that discuss and share their knowledge about the latest developments of the virus.
EASL-WHO webinar on COVID-19 and the liver
Testimonials on dealing with the public health crisis
EASL Viewpoints are testimonials, interviews, and videos from healthcare professionals sharing life from the frontlines, across Europe.
In their testimonials, hepatologists, liver nurses, researchers, and academics tell how their working life has been affected by COVID-19 and what might be to come.
France, Italy, Portugal, Sweden, the UK… and more to come – watch the videos, read the interviews, and get to meet members of the hepatology community.
COVID-19 related papers from the Journal of Hepatology and JHEP Reports
The “EASL COVID-19 article collection” houses articles dealing with COVID-19 and the liver published in EASL’s two journals, Journal of Hepatology and JHEP Reports. This initiative aims at facilitating access to research that can be critically relevant for the treatment of liver patients during the pandemic.
News from the EASL supported COVID-Hep registry
Press release, 21/05/2020
A new international study has found increased mortality rates from COVID-19 among people with chronic liver disease and cirrhosis and has called for patients with worsening liver function to be tested for coronavirus.
The researchers, led by teams at Oxford University Hospitals NHS Foundation Trust and the University of North Carolina, set up an international registry (the EASL supported COVID-hep registry, see below) to collect clinical details of patients with chronic liver disease and cirrhosis who develop COVID-19. Between 25 March 2020 and 20 April 2020, 152 cases were submitted to the registry, over 95% of which were hospitalised. Patients with cirrhosis had poor outcomes with an overall death rate of 40 percent. Those with advanced disease called decompensated cirrhosis had the highest rate of death (between 43 and 63 percent), compared with 12 percent for patients with liver disease but without cirrhosis.
The EASL supported COVID-Hep registry was launched at the University of Oxford, UK on 23 March 2020. The registry is collecting data on patients, with liver disease at any stage or liver transplants, that have also developed laboratory-confirmed COVID-19. On 21 May, a study based on the first 152 consecutive submissions was published in the Journal of Hepatology
As of 19 June, according to the week 12 report (downloadable), data collected (combined with data from SECURE-cirrhosis, who are covering the Americas, China, Japan, and Korea) has grown to 833 cases, from at least 31 countries, including 151 liver transplant recipients. Browse the weekly updates.
Care of patients with liver disease during the COVID-19 pandemic: EASL-ESCMID Position Paper
In response to the COVID-19 pandemic, EASL and the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) have issued a Position Paper providing recommendations for clinicians on caring for patients with liver diseases and for liver transplant recipients. The joint Position Paper also provides a flowchart and an overview of current treatment options, to help clinicians with decision-making during this resource-strapped time.
Journal of Hepatology call for papers on COVID-19
The outbreak of COVID-19 (coronavirus) is of great concern and a considerable challenge for practitioners and public health authorities. Following the initiative of other leading scientific journals, we believe that it is timely, important, and appropriate to share with our Journal of Hepatology readers, as soon as possible, all information available on the possible impact of the infection on the liver and on patients with liver diseases.
We therefore invite authors to send their original data on these topics. We will provide authors with a rapid evaluation and, if their articles are accepted, free access to their content. Of course, as an obligation to our community, we will ensure the same high standards of scientific review for these articles.
External resources on COVID-19
Public health resources
European Centre for Disease Prevention and Control: COVID-19
European Centre for Disease Prevention and Control: today’s data on geographic distribution of COVID-19 cases worldwide
European Commission: Coronavirus response
European Commission: Public health
European Medicines Agency: Coronavirus disease (COVID-19)
World Health Organization: Coronavirus disease (COVID-19) outbreak
World Health Organization: Coronavirus disease (COVID-19) Pandemic
World Health Organization: Q&A on coronaviruses (COVID-19)
British Medical Journal: Coronavirus (covid-19): Latest news and resources
Cell Press: COVID-19 Resource Hub
The Lancet: COVID-19 Resource Centre
New England Journal of Medicine: Coronavirus (Covid-19)
Science: Coronavirus: Research, Commentary, and News
COVID-19 and the liver
The Lancet: COVID-19 and the liver: little cause for concern
The Lancet: Liver injury in COVID-19: management and challenges
Wiley Online, Liver International: Liver injury during highly pathogenic human coronavirus infections
Open access scientific articles
Cell.com: Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein
Journal of Clinical Microbiology: The emergence of a novel coronavirus (SARS-CoV-2), their biology and therapeutic options
Nature: Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus
Nature: Epidemiological data from the COVID-19 outbreak, real-time case information
Nature: Network-based drug repurposing for novel coronavirus 2019-nCoV/SARS-CoV-2
BioMed Alliance submits Joint Statement to EU leaders, as COVID-19 threatens medical associations
Subsequent to the disruption caused by the COVID-19 pandemic, EASL and 32 other leading European medical associations – together forming the Biomedical Alliance in Europe (BioMed Alliance) – have submitted a joint statement to EU leaders.